Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Can the APOEε4 genotype contribute to tau pathology progression?

João Pedro Ferrari-Souza • 25 Nov 2022
CTAD 2022
Alzheimer’s Disease Dementia

João Pedro Ferrari-Souza, MD-PhD student, University of Pittsburgh, Pittsburgh, shares insights into his current work investigating how the APOEε4 genotype and amyloid-β associate with each other and how this contributes to tau pathology progression. This interview took place at the Clinical Trials on Alzheimer’s Disease congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from João Pedro Ferrari-Souza

APOEε4 drives tau accumulation through Aβ-dependent and Aβ-independent pathways
1:47
APOEε4 drives tau accumulation through Aβ-dependent and Aβ-independent pathways
João Pedro Ferrari-Souza • 22 Mar 2023
APOEε4 drives Aβ-dependent formation of tau tangles
4:27
APOEε4 drives Aβ-dependent formation of tau tangles
João Pedro Ferrari-Souza • 22 Mar 2023
APOEε4 triggers early microglial activation in Alzheimer’s disease
2:42
APOEε4 triggers early microglial activation in Alzheimer’s disease
João Pedro Ferrari-Souza • 22 Mar 2023
Astrocyte biomarkers associated with amyloid-β and tau pathologies
2:25
Astrocyte biomarkers associated with amyloid-β and tau pathologies
João Pedro Ferrari-Souza • 25 Nov 2022

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals